GMO's Benchmark-Free Allocation Strategy did very well over the past decade because its big asset class bets won.

Judge as of April 2012, over roughly the preceding decade (about 2002-2012). The claim has two parts: (a) the strategy performed very well, and (b) it did so because its big asset-allocation bets were right. True: GMO's published performance for the Benchmark-Free Allocation Strategy (or its predecessor composite) shows clearly strong annualised returns over the decade, beating its stated benchmark or target (e.g. CPI+5%) and broad references such as MSCI ACWI or a 60/40 blend, with lower drawdowns. Also, GMO's or independent attribution credits most of that result to asset-class positioning, such as being underweight equities before 2008, or emerging markets, quality or bond calls. Mostly true: returns were strong and asset-allocation bets were a major driver, but a minor detail is off, for example the track record is somewhat shorter than ten years or it trailed one reference over part of the period. Mixed: only one part holds, for example returns were good but came mainly from security selection rather than asset-class bets, or the result is mixed across references. Mostly false: performance was only roughly in line with benchmarks, and 'very well' overstates a modest edge. False: the strategy underperformed its benchmark or target over the decade, or its big bets visibly lost.

Set before the research began.

1. E1 25 Years of Benchmark-Free Investing GMO · 23 July 2026 Own record

   “The traditional portfolio is 60% MSCI ACWI/40% Bloomberg U.S. Aggregate Bond. The 5% real, 5.5% real, and 5.75% real portfolios are monthly rebalanced portfolios of the Bloomberg U.S. TIPS Index”

2. E2 25 Years of Benchmark-Free Investing GMO · 23 July 2026 Own record

   “The portfolios we suggested, on the other hand, achieved somewhat higher returns than we forecast, comfortably exceeding the 5% real return hurdle that investors generally need.”

3. E3 25 Years of Benchmark-Free Investing GMO · 23 July 2026 Own record

   “The Benchmark-Free Allocation Strategy, whose goal has been to achieve a real return of 5% with risk similar to or less than that of a traditional 60/40 portfolio, has delivered 5.7% real net of fees since inception, against 4.0% real for 60/40.”

4. E4 25 Years of Benchmark-Free Investing GMO · 23 July 2026 Own record

   “Second, achieving that track record came with substantial periods of relative underperformance when traditional portfolios were flying high, and ours were not.”

5. E5 Composite Descriptions GMO (Grantham, Mayo, Van Otterloo & Co. LLC) Own record

   “We also seek to add value through security selection within both traditional and alternative asset classes. The composite was created in September 2012.”

6. E6 25 Years of Benchmark-Free Investing GMO · 23 July 2026 Own record

   “At that time, our asset allocation portfolios were seriously underperforming their benchmarks, and our persuasive power was understandably at an ebb.”

7. E7 25 Years of Benchmark-Free Investing GMO · 23 July 2026 Own record

   “We also benefited from our willingness to aggressively move into undervalued assets in the early 2000s and over the last couple of years.”

8. E8 25 Years of Benchmark-Free Investing GMO · 23 July 2026 Own record

   “The Benchmark-Free Allocation Strategy, whose goal has been to achieve a real return of 5% with risk similar to or less than that of a traditional 60/40 portfolio, has delivered 5.7% real net of fees since inception, against 4.0% real for 60/40.”

9. E9 GMO Benchmark-Free Allocation Fund Is Light On Stocks Seeking Alpha (article by MyPlanIQ) · 19 January 2012

   “From 2004 to 2007, the fund had over 10% annualized returns for 4 consecutive years. The fund navigated through the financial crisis smartly. It only lost 11.23% in 2008 and recovered 20.65% in 2009.”

10. E10 GMO Benchmark-Free Allocation Fund Is Light On Stocks Seeking Alpha (article by MyPlanIQ) · 19 January 2012

    “However, its performance in 2010 was a bit disappointing, only gaining 4.91%.”

11. E11 GMO Benchmark-Free Allocation Fund Is Light On Stocks Seeking Alpha (article by MyPlanIQ) · 19 January 2012

    “The fund returned annually 5.6% and 10% in last 5 years and 3 years, respectively.”

12. E12 GMO Quarterly Letter Advisor Perspectives · 25 January 2019 Own record

    “a far cry from the 26% loss such a portfolio suffered in 2008”

An independent January 2012 article reports annual returns above 10% for 2004-2007, a 2008 loss of 11.23% and annualised returns of 5.6% over five years and 10% over three (E9, E11). It notes a weak 2010 (E10) but gives no comparison with CPI+5%, MSCI ACWI or a 60/40 benchmark. Only GMO's own 2026 whitepaper credits asset-class moves in the early 2000s (E7); the same paper also says its portfolios had substantial periods of relative underperformance, without dating them to 2002-2012 (E4). The composite was only created in September 2012 (E5). The evidence does not establish the decade-long benchmark comparison or independent attribution the criteria require.